Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery

Gharse, Sachin; Fiegel, Jennifer

doi:10.2174/1381612822666160128145356

Cited by 42 publications

(25 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since AS is a-first-line agent for treatment and prevention of bronchospasm in patients with asthma and chronic obstructive pulmonary disease,62,63 the pharmacodynamic properties of AS-BSA-NPs should confer benefits to these patients via the targeted and rapid release of a bronchodilator after NPs arrive at the distal bronchi. Large hollowed NP aggregates have many merits, including prolonging drug release, enhanced drug utilization, and alleviation of administration frequency, giving rise to improved patient compliance 64,65. As a consequence, we plan to prepare large hollowed NP aggregates66 based on AS-BSA-NPs to improve lung drug deposition via dry-powder inhalation to enhance therapeutic efficacy.…”

Section: Discussionmentioning

confidence: 99%

Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway

Lin¹,

Lee²,

Zhang³

et al. 2016

DDDT

View full text Add to dashboard Cite

Fenretinide is a novel anticancer agent reported to exhibit anti-invasive and antimetastatic activities. It has also been shown to improve obesity and diabetes, although the effects of fenretinide on hypertension are still unknown, and the detailed mechanisms remain unclear. In this study, we have shown that treatment with lipopolysaccharide (LPS) decreased the expression of peroxisome proliferator-activated receptor γ (PPARγ) in RAW264.7 macrophages, and pretreatment with fenretinide reversed the effect of LPS on PPARγ expression. In addition, LPS-induced pro-inflammatory cytokine production, including tumor necrosis factor-α, interleukin 6, and monocyte chemoattractant protein 1 were dose-dependently reversed by fenretinide, and the effects of fenretinide on LPS-induced pro-inflammatory cytokine production were blocked by treatment with PPARγ antagonist. Moreover, fenretinide decreased LPS-induced inducible nitric oxide synthase expression and nitrogen oxide production. These effects were blocked by the pretreatment with PPARγ antagonist in a dose-dependent manner, indicating fenretinide activated PPARγ to exert anti-inflammation activity. In view of the role of inflammation in hypertension and the anti-inflammatory action of fenretinide, we found that administration of fenretinide in spontaneously hypertensive rats significantly decreased blood pressure. Taken together, these results indicate that fenretinide might be a potent antihypertensive agent that works by suppressing inflammation via activating PPARγ.

show abstract

Section: Discussionmentioning

confidence: 99%

Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway

Lin¹,

Lee²,

Zhang³

et al. 2016

DDDT

View full text Add to dashboard Cite

show abstract

“…Therefore, longer residence time was observed with MP of geometric diameter ≥ 20 μm being too large to be phagocytosed by alveolar macrophages. Therefore, particles should be light with large geometric diameter and low aerodynamic diameter to achieve deep delivery into lungs [ 68 ]. Garcia-Contreras et al formulated large porous particles for treatments of tuberculosis in guinea-pig model [ 69 ].…”

Section: Nanotechnology and Microparticles Based Applications For Covmentioning

confidence: 99%

COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic

et al. 2020

View full text Add to dashboard Cite

The recent corona virus disease (COVID-19) outbreak has claimed the lives of many around the world and highlighted an urgent need for experimental strategies to prevent, treat and eradicate the virus. COVID-19, an infectious disease caused by a novel corona virus and no approved specific treatment is available yet. A vast number of promising antiviral treatments involving nanotechnology are currently under investigation to aid in the development of COVID-19 drug delivery. The prospective treatment options integrating the ever-expanding field of nanotechnology have been compiled, with the objective to show that these can be potentially developed for COVID-19 treatment. This review summarized the current state of knowledge, research priorities regarding the pandemic and post COVID-19. We also focus on the possible nanotechnology approaches that have proven to be successful against other viruses and the research agenda to combat COVID-19.

show abstract

“…Large hollowed NP aggregates have many merits, including prolonging drug release, enhanced drug utilization, and alleviation of administration frequency, giving rise to improved patient compliance. 64 , 65 As a consequence, we plan to prepare large hollowed NP aggregates 66 based on AS-BSA-NPs to improve lung drug deposition via dry-powder inhalation to enhance therapeutic efficacy.…”

Section: Discussionmentioning

confidence: 99%

Combined computational and experimental studies of molecular interactions of albuterol sulfate with bovine serum albumin for pulmonary drug nanoparticles

Lin

Cui

Wang

et al. 2016

DDDT

View full text Add to dashboard Cite

Albumin-based nanoparticles (NPs) are a promising technology for developing drug-carrier systems, with improved deposition and retention profiles in lungs. Improved understanding of these drug–carrier interactions could lead to better drug-delivery systems. The present study combines computational and experimental methods to gain insights into the mechanism of binding of albuterol sulfate (AS) to bovine serum albumin (BSA) on the molecular level. Molecular dynamics simulation and surface plasmon resonance spectroscopy were used to determine that there are two binding sites on BSA for AS: the first of which is a high-affinity site corresponding to AS1 and the second of which appears to represent the integrated functions of several low-affinity sites corresponding to AS2, AS3, and AS8. AS1 was the strongest binding site, established via electrostatic interaction with Glu243 and Asp255 residues in a hydrophobic pocket. Hydrogen bonds and salt bridges played a main role in the critical binding of AS1 to BSA, and water bridges served a supporting role. Based upon the interaction mechanism, BSA NPs loaded with AS were prepared, and their drug-loading efficiency, morphology, and -release profiles were evaluated. Successful clinical development of AS-BSA-NPs may improve therapy and prevention of bronchospasm in patients with reversible obstructive airway disease, and thus provide a solid basis for expanding the role of NPs in the design of new drug-delivery systems.

show abstract

Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery

Cited by 42 publications

References 67 publications

Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway

Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway

COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic

Combined computational and experimental studies of molecular interactions of albuterol sulfate with bovine serum albumin for pulmonary drug nanoparticles

Contact Info

Product

Resources

About